Results 121 to 130 of about 782 (172)

Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment. [PDF]

Oncogene
Narayana RVL, Gupta R.
europepmc   +1 more source

Editorial: In celebration of women in science: Lipids, membranes, and membranous organelles. [PDF]

Front Mol Biosci, 2023
López-Lara IM, Govorunova EG.
europepmc   +1 more source

Carcinogenesis Associated with Toxin Nephropathy: Proposed Mediation by Phosphate Toxicity. [PDF]

Cells
Brown RB, Mielke JG.
europepmc   +1 more source

Dolaflexin_Figure1 from The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b

, 2023
Natalya D. Bodyak, Rebecca Mosher, Aleksandr V. Yurkovetskiy, Ying Mao, Charlie Bu, Patrick R. Conlon, Damon R. Demady, Michael J. DeVit, Dmitry R. Gumerov, Venu R. Gurijala, Winnie Lee, Dennis J. McGillicuddy, Peter U. Park, Laura L. Poling, Marina Protopova, LiuLiang Qin, Cheri A. Stevenson, Elena Ter‐Ovanesyan, Alex Uttard, Dongmei Xiao, Jian Xu, Ling Xu, Donald A. Bergstrom, Timothy B. Lowinger   +23 more
openalex   +1 more source

Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective. [PDF]

Med Sci Monit
Abramiuk M, Skrabalak I, Satora M, Ostrowska-Leśko M, Czech MJ, Majchrzak J, Bobiński M.   +6 more
europepmc   +1 more source

TUB-040, a homogenous and hydrophilic NaPi2b-targeting ADC with stably linked exatecan, exhibits long-lasting anti-tumor activity and a well-tolerated safety profile

Annette M. Vogl, Saskia Schmitt, Isabelle Mai, Paul Machui, Sarah Herterich, N. Leonardi, Philipp Cyprys, Danila Hauswald, Philipp Ochtrop, Izabela Kozlowska, Annabel Kitowski, Marcus Gerlach, Florian Waldmann, Olivier Marcq, Pamela A. Trail, Dominik Schumacher, Günter R. Fingerle-Rowson, Björn Hock, Marc‐André Kasper, Jonas Helma   +19 more
openalex   +1 more source

The sodium-dependent phosphate transporter NaPi2b is a new target antigen in ovarian carcinoma and is recognized by the anti- cancer antibody MX35

European Journal of Cancer Supplements, 2008
Vadym Gurtovyy, Gerd Ritter, Ivan Gout, B. Yin, Y. Khozayenko, V. S. Usenko, V. V. Filonenko, Vitalina Gryshkova, Ramziya Kiyamova   +8 more
openaire   +2 more sources

Advancing Ovarian Cancer Therapeutics: The Role of Targeted Drug Delivery Systems. [PDF]

Int J Nanomedicine
Lin Q, Li J, Abudousalamu Z, Sun Y, Xue M, Yao L, Chen M.   +6 more
europepmc   +1 more source

Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses. [PDF]

Nat Commun
Malli Cetinbas N, Monnell T, Soomer-James J, Shaw P, Lancaster K, Catcott KC, Dolan M, Mosher R, Routhier C, Chin CN, Toader D, Duvall J, Bukhalid R, Lowinger TB, Damelin M.   +14 more
europepmc   +1 more source

Prevalence and Prognostic Significance of Sodium-Dependent Phosphate Transporter 2B (Napi2B) Protein Expression in Non-Small Cell Lung Cancer (Nsclc)

, 2014
M. D’Arcangelo, Odd Terje Brustugun, Yang Xiao, YJ Choi, Carmen Behrens, Luisa M. Solis, Y. Wang, Ron Firestein, T.A. Boyle, Marius Lund‐Iversen, Chris Rivard, Åslaug Helland, Ignacio I. Wistuba, Fred R. Hirsch, D. Shames   +14 more
openalex   +1 more source